Naoero vs Tonga: The number of people with susceptibility test result for rifampicin
Naoero
100
in 2021
Tonga
100
in 2021
Naoero rank
2nd
Tonga rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Naoero
- Tonga
How they compare
Naoero currently reports 100 against 100 in Tonga, a difference of 0.
Across all 5 years both countries report, Tonga has been ahead every year.
Naoero ranks 2nd and Tonga ranks 2nd of 146 countries.
Tonga has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Naoero | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0 | 100 | 100 | Tonga |
| 2020s | 50 | 100 | 50 | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Naoero or Tonga?
- Naoero, at 100 against 100 in Tonga as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Naoero and Tonga?
- 0, with Naoero ahead.
- How many years of comparable data are there for Naoero and Tonga?
- 5 years are reported by both, from 2017 to 2021.
- How do Naoero and Tonga rank globally for the number of people with susceptibility test result for rifampicin?
- Naoero ranks 2nd and Tonga ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.